Literature DB >> 27294063

An analysis of dermatological quality-of-life scores in relation to psychiatric morbidity in psoriasis.

Shubh Mohan Singh1, Tarun Narang2, Sunil Dogra2, Anant Kumar Verma3, Sunil Gupta4, Sanjeev Handa2.   

Abstract

Entities:  

Year:  2016        PMID: 27294063      PMCID: PMC4886600          DOI: 10.4103/2229-5178.182371

Source DB:  PubMed          Journal:  Indian Dermatol Online J        ISSN: 2229-5178


× No keyword cloud information.
Psoriasis is a common immune-mediated, chronic skin disorder with significant impact on Quality of life (QOL) of the patient.[1] The Dermatology Life Quality Index (DLQI) is a commonly used instrument to assess QOL in psoriasis.[23] The DLQI consists of 10 patient-rated items with a maximum score of 30. The 10 items are grouped under six headings.[3] Impairments in QOL seem to be associated with the development of psychiatric disorders in psoriasis.[4] Although DLQI scoring is used in a variety of research settings in psoriasis, data regarding the contribution of individual headings to the final score is scarce. We report the results of an analysis of DLQI scores in patients with psoriasis who were then evaluated for presence of any psychiatric disorder. This study was carried out as a part of a larger study that investigated the prevalence and determinants of psychiatric disorders in patients with psoriasis. This study was conducted from January to November 2013 in a tertiary care hospital in north India after clearance from the institutional ethics committee. Consecutive patients with chronic plaque psoriasis who provided written informed consent were included in the study. Patients with psoriatic arthritis, erythrodermic and pustular variants of psoriasis were excluded. In the first stage, sociodemographic details were noted and participants were assessed by a dermatologist for clinical details and the Psoriasis Area Severity Index (PASI).[5] Participants were also asked to fill out the DLQI. In the second stage, patients were assessed by a psychiatrist and a psychiatric diagnosis was generated using the Mini International Neuropsychiatric Interview (MINI) [Table 1].[6] Data were then analyzed. using SPSS software (Version 18.0) for Windows. Wald test was used for regression analysis.
Table 1

Diagnostic groups and diagnoses generated by MINI

Diagnostic groups and diagnoses generated by MINI A total of 104 patients (79 males and 25 females) with a mean age of 36.49 years (standard deviation = 13.79) consented to participate in the study. The mean PASI was 6.67 (standard deviation = 6.16) and mean DLQI score was 6.85 (standard deviation 6.22). The PASI and DLQI scores indicate that most patients were suffering from mild-to-moderate psoriasis.[7] Forty-seven patients had at least one MINI diagnosis. Depressive disorders (DD) were the most common diagnoses, prevalence of DD was 39.4% and majority of them had dysthymia (28.84%). About 7% patients had more than one MINI diagnosis. The results of the study are presented in Table 2. A regression analysis (Wald test) with the scores of the different headings as covariates and a positive MINI diagnosis as the dependent variable was carried out. It revealed that the score of the heading of symptoms and feelings predicted a MINI diagnosis (Wald = 8.721, P = 0.003).
Table 2

Correlation between quality of life and psychiatric comorbidity

Correlation between quality of life and psychiatric comorbidity The mean scores across each heading of the DLQI and the total were significantly more in the group with any diagnosed psychiatric disorder. However, the percentages of contribution of the mean score of each heading to the total mean DLQI score was not significantly different across the two groups. The percentages of contribution of individual headings show that in our sample, symptoms and feelings contributed most to the total score. On the other hand, the headings of Leisure and Personal relationships were not endorsed as much. Our study suggests that feelings and reactions to the symptoms of disease is the main contributor to impaired QOL in patients with mild-to-moderate psoriasis and also predicts psychiatric morbidity. The headings of Daily activities, Work and school, and Treatment “performed as expected.” The results also suggest that impairments in leisure and personal relationships are either not affected as much in mild-to-moderate psoriasis or are deemed to be relatively unimportant. This may be reflective of socioeconomic reasons that prevent many patients in our country to indulge or give due importance to meaningful leisure or sport activities or cultural reasons that prevent sufferers from responding readily to enquiries about sexual issues. Responses on personal or sexual issues are limited by patients because of social prohibitive reasons. It might be interesting to see these responses in more educated patients from urban settings who understand their anonymity and the idea of this being a research tool. In light of the high prevalence of psychiatric disorders in this population and the obvious contribution of impairment in QOL to the same, the question of the socioeconomic–cultural applicability of the items used in measurement of QOL becomes important.[8] Our results suggest that emotional reactions to the symptoms of the disease are a major contributor to the impairment in QOL and should be given more importance in QOL measurements. An exploration of QOL in patients with even mild-to-moderate psoriasis is warranted. Although it does not imply that impairment of QOL results in psychiatric comorbidities or vice versa; greater impairments reflected in higher DLQI scores may warrant screening for psychiatric disorders, especially DD. Active management of symptoms and a sympathetic exploration of reactive emotions along with need-based referral to psychiatric services are likely to be important in the improvement of QOL in patients with mild-to-moderate psoriasis.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  8 in total

1.  Dermatology life quality index: time to move forward.

Authors:  Tamar Nijsten
Journal:  J Invest Dermatol       Date:  2012-01       Impact factor: 8.551

Review 2.  The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results.

Authors:  M K A Basra; R Fenech; R M Gatt; M S Salek; A Y Finlay
Journal:  Br J Dermatol       Date:  2008-09-15       Impact factor: 9.302

3.  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Authors:  A Y Finlay; G K Khan
Journal:  Clin Exp Dermatol       Date:  1994-05       Impact factor: 3.470

4.  The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.

Authors:  Shanu Kohli Kurd; Andrea B Troxel; Paul Crits-Christoph; Joel M Gelfand
Journal:  Arch Dermatol       Date:  2010-08

Review 5.  Quality of life in patients with psoriasis: a systematic literature review.

Authors:  John de Korte; Mirjam A Sprangers; Femke M Mombers; Jan D Bos
Journal:  J Investig Dermatol Symp Proc       Date:  2004-03

6.  Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.

Authors:  Richard G Langley; Charles N Ellis
Journal:  J Am Acad Dermatol       Date:  2004-10       Impact factor: 11.527

Review 7.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

8.  Definition of treatment goals for moderate to severe psoriasis: a European consensus.

Authors:  U Mrowietz; K Kragballe; K Reich; P Spuls; C E M Griffiths; A Nast; J Franke; C Antoniou; P Arenberger; F Balieva; M Bylaite; O Correia; E Daudén; P Gisondi; L Iversen; L Kemény; M Lahfa; T Nijsten; T Rantanen; A Reich; T Rosenbach; S Segaert; C Smith; T Talme; B Volc-Platzer; N Yawalkar
Journal:  Arch Dermatol Res       Date:  2010-09-21       Impact factor: 3.017

  8 in total
  2 in total

1.  General measures and quality of life issues in psoriasis.

Authors:  Rashmi Sarkar; Shikha Chugh; Shivani Bansal
Journal:  Indian Dermatol Online J       Date:  2016 Nov-Dec

2.  Therapeutic Inertia in the Management of Psoriasis: A Quantitative Survey Among Indian Dermatologists and Patients.

Authors:  Murlidhar Rajagopalan; Sunil Dogra; Kiran Godse; Bikash Ranjan Kar; Sai Krishna Kotla; Shekhar Neema; Abir Saraswat; Swapnil Deepak Shah; Nina Madnani; Vidyadhar Sardesai; Rajiv Sekhri; Sachin Varma; Sandeep Arora; Pallavi Kawatra
Journal:  Psoriasis (Auckl)       Date:  2022-08-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.